Main Article Content
Abstract
Background: The pharmaceutical development process is inherently complex, resource-intensive, and time-consuming, with formulation scientists navigating a multidimensional experimental space of drug properties, excipient choices, manufacturing process parameters, and quality attributes whose interrelationships are often non-linear and poorly understood from first principles alone. Artificial intelligence and machine learning offer a transformative shift in how this experimental space is explored, replacing exhaustive trial-and-error experimentation with data-driven predictive models that can identify optimal formulation compositions, predict quality attributes from compositional inputs, and guide experimental design toward the most informative experiments from a sparse dataset.
Objective: This review critically examines the application of artificial intelligence and machine learning methodologies — including artificial neural networks, random forest, support vector machines, Gaussian process regression, deep learning, and generative models — to pharmaceutical formulation development, covering solubility prediction, dissolution modeling, stability forecasting, nanoparticle optimization, and integration with Quality by Design frameworks, based on literature published up to 2023.
Results and Discussion: Machine learning models trained on physicochemical descriptors have achieved prediction accuracy for aqueous solubility, intestinal permeability, and oral bioavailability comparable to or exceeding mechanistic models, with random forest and deep neural network architectures consistently outperforming linear regression and multiple regression approaches on diverse pharmaceutical datasets. Bayesian optimization has emerged as the most efficient strategy for formulation parameter optimization with minimal experimental trials. Natural language processing applied to pharmaceutical literature enables automated extraction of formulation knowledge at a scale inaccessible to manual review.
Conclusion: Artificial intelligence and machine learning are rapidly transitioning from exploratory pharmaceutical research tools to integral components of industrial formulation development pipelines, with demonstrated capabilities in predictive modeling, process optimization, and quality by design implementation that reduce development timelines and experimental burden. The interpretability of models, data quality requirements, and regulatory acceptance of AI-assisted development decisions are the primary barriers requiring systematic resolution.